SecSonar.com

United Therapeutics Corporation (UTHR)

United Therapeutics Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

United Therapeutics Corporation (UTHR) is a Biotechnology company based in US with a market capitalization of $23.4B. Revenue grew 10.6% year-over-year and the company generated $1B in free cash flow. This page tracks UTHR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 1.31K employees · IPO Jun 17, 1999

Valuation

Valuation & price

$568.58 · as of May 17, 2026 · -4.7% vs 52w high

20.4

P/E ratio

Latest-FY diluted EPS

3.30

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$597$436$275Jul 25Dec 25Jul 26Jul 7, 25$290.39Jul 9, 25$300.56Jul 11, 25$295.52Jul 15, 25$293.24Jul 17, 25$297.33Jul 21, 25$293.12Jul 23, 25$305.61Jul 25, 25$304.50Jul 29, 25$297.56Jul 31, 25$274.70Aug 4, 25$292.65Aug 6, 25$302.41Aug 11, 25$300.43Aug 13, 25$309.72Aug 15, 25$313.13Aug 19, 25$313.22Aug 21, 25$310.66Aug 25, 25$305.38Aug 27, 25$305.35Aug 29, 25$304.76Sep 3, 25$391.45Sep 5, 25$400.52Sep 9, 25$403.80Sep 11, 25$404.84Sep 16, 25$397.97Sep 18, 25$409.87Sep 22, 25$414.73Sep 24, 25$438.75Sep 26, 25$432.66Sep 30, 25$419.21Oct 2, 25$443.44Oct 6, 25$453.28Oct 8, 25$448.93Oct 10, 25$440.00Oct 14, 25$433.61Oct 16, 25$432.69Oct 21, 25$422.53Oct 23, 25$426.21Oct 27, 25$421.04Oct 29, 25$455.32Oct 31, 25$445.43Nov 4, 25$437.33Nov 6, 25$454.00Nov 10, 25$453.93Nov 12, 25$461.54Nov 14, 25$466.40Nov 18, 25$476.59Nov 20, 25$474.72Nov 25, 25$485.77Nov 28, 25$486.00Dec 2, 25$474.14Dec 4, 25$484.10Dec 8, 25$479.51Dec 10, 25$484.86Dec 12, 25$493.99Dec 16, 25$500.00Dec 18, 25$507.00Dec 22, 25$513.79Dec 24, 25$514.64Dec 29, 25$502.90Jan 2, 26$496.72Jan 6, 26$502.71Jan 8, 26$490.83Jan 12, 26$482.39Jan 14, 26$475.73Jan 16, 26$464.93Jan 21, 26$469.77Jan 23, 26$468.94Jan 27, 26$476.78Jan 29, 26$467.70Feb 2, 26$475.00Feb 4, 26$482.59Feb 9, 26$473.12Feb 11, 26$475.85Feb 13, 26$473.66Feb 18, 26$476.05Feb 20, 26$473.42Feb 24, 26$473.43Feb 26, 26$503.60Mar 2, 26$513.82Mar 4, 26$490.21Mar 6, 26$478.16Mar 10, 26$535.81Mar 12, 26$532.82Mar 17, 26$540.02Mar 19, 26$527.00Mar 23, 26$521.22Mar 25, 26$541.60Mar 27, 26$522.83Mar 31, 26$592.98Apr 2, 26$564.81Apr 7, 26$565.70Apr 9, 26$574.77Apr 13, 26$577.63Apr 15, 26$577.58Apr 17, 26$588.38Apr 22, 26$574.29Apr 24, 26$567.16Apr 28, 26$569.11Apr 30, 26$571.35May 4, 26$581.22May 6, 26$596.76May 8, 26$564.94May 12, 26$581.74May 14, 26$575.79May 18, 26$566.99May 20, 26$563.93May 22, 26$568.43May 28, 26$562.09Jun 1, 26$544.62Jun 3, 26$549.47Jun 5, 26$549.87Jun 9, 26$553.14Jun 11, 26$545.40Jun 15, 26$549.57Jun 17, 26$551.47Jun 22, 26$538.30Jun 24, 26$549.90Jun 26, 26$542.66Jul 2, 26$555.91
$274.7052-week range$596.76
Loading valuation history…

Fundamentals

Key fundamentals

$23.4B

Market cap

10.6%

Revenue growth (YoY)

87.9%

Gross margin

$1B

Free cash flow (USD)

-$1.6B

Net debt

Net cash position

-2.0%

Share dilution

3/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.6BFY 2017$1.7BFY 2018$1.6BFY 2019$1.4BFY 2020$1.5BFY 2021$1.7BFY 2022$1.9BFY 2023$2.3BFY 2024$2.9BFY 2025$3.2B
$1.6B$3.2B

Free cash flow by year

2016 → 2025

FY 2016$600.4MFY 2017$387.9MFY 2018$594.0MFY 2019$-290.3MFY 2020$696.4MFY 2021$477.4MFY 2022$663.7MFY 2023$747.6MFY 2024$1.1BFY 2025$1.0B
$600.4M$1B

Gross margin by year

2021 → 2025

FY 202192.7%FY 202292.4%FY 202388.9%FY 202489.2%FY 202587.9%
92.7%87.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

6

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $5.3M · 10b5-1 PlanROTHBLATT MARTINE A · Director, Chairperson & CEO · $5.3MJul 2, 2026Filing
  • 8-K eventStock Incentive PlanJun 29, 2026Filing
  • Insider sellInsider Sell $5.2M · 10b5-1 PlanROTHBLATT MARTINE A · Director, Chairperson & CEO · $5.2MJun 26, 2026Filing
  • Insider sellInsider Sell $5.2M · 10b5-1 PlanROTHBLATT MARTINE A · Director, Chairperson & CEO · $5.2MJun 25, 2026Filing
  • Insider sellInsider Sell $5.1M · 10b5-1 PlanROTHBLATT MARTINE A · Director, Chairperson & CEO · $5.1MJun 24, 2026Filing
  • Insider sellInsider Sell $4.7M · 10b5-1 PlanEDGEMOND JAMES · CFO AND TREASURER · $4.7MJun 23, 2026Filing
  • Insider sellInsider Sell $5.4M · 10b5-1 PlanEDGEMOND JAMES · CFO AND TREASURER · $5.4MJun 22, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing

Questions

Frequently asked questions

What is United Therapeutics Corporation's market cap?

United Therapeutics Corporation (UTHR) has a market capitalization of $23.4B.

What is UTHR's P/E ratio?

UTHR trades at a price-to-earnings ratio of 20.4, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is UTHR's price-to-book (P/B) ratio?

UTHR trades at 3.30 times book value per share.

Are insiders buying UTHR stock?

SEC Form 4 filings show no open-market insider buys at United Therapeutics Corporation in the last 90 days (6 sells).

Same arena

Related companies in Biotechnology

INSM

Insmed Incorporated

$23.3B

RPRX

Royalty Pharma plc

$23.6B

ROIV

Roivant Sciences Ltd.

$21.7B

INCY

Incyte Corporation

$19.5B

MRNA

Moderna, Inc.

$19.3B

GMAB

Genmab A/S

$16.3B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.